PATENT CLAIM ANALYSIS

Application Number: 15906930
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["435", "458000"]

Abstract:
A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5′ terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5′ terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.

Claim (Index 3):
The cell of  claim 2 , wherein the cell is HEK293 cell.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 2.20833
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14235333', '10529221', '15328997', '12034737', '11395197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5965283189371113
- 35 USC 102 Novelty (BERT): 0.5413067723342029
- Combined Prediction Score: 0.5910061642768205
- Mean Citation Score: 251.77357
- Max Citation Score: 406.59174
- Similarity Product: 224.52449859886408

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test